I ACTG 245, et dobbeltblindt, placebokontrolleret forsøg, var forekomsten af alvorlig, lægemiddelrelateret granulocytopeni 5/ 305 (1, 6%).
In ACTG 245, a double-blind placebo controlled study, the frequency of serious drug-related granulocytopenia was 5/ 305 (1.6%).